Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)

Historical Holders from Q2 2019 to Q3 2025

Symbol
TRVI on Nasdaq
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
121,543,157
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
129,323,951
Holdings value
$1,183,258,435
% of all portfolios
0.004%
Number of holders
163
Number of buys
99
Number of sells
-64
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
New Enterprise Associates 16, L.P. 12% -20% $98,735,224 15,074,080 0% New Enterprise Associates 16, L.P. 07 Aug 2025
Rubric Capital Management LP 7.12% +48.2% $42,659,300 +$21,633,655 8,531,860 +1% Rubric Capital Management LP 30 Jun 2025
Frazier Life Sciences Public Fund, L.P. 7% -32.7% $77,848,392 -$16,025,200 8,508,021 -17.1% Frazier Life Sciences Public Fund, L.P. 30 Sep 2025
BlackRock, Inc. 5.6% $62,259,693 6,804,338 BlackRock, Inc. 30 Sep 2025
VIKING GLOBAL INVESTORS LP 4.2% -28.3% $46,929,206 -$21,747,894 5,128,875 -31.7% VIKING GLOBAL INVESTORS LP 30 Sep 2025
Venrock Healthcare Capital Partners II, L.P. 1.4% $8,042,002 1,266,457 Venrock Healthcare Capital Partners II, L.P. 31 Dec 2024
Rosalind Advisors, Inc. 1.2% $6,746,875 1,062,500 Rosalind Advisors, Inc. 13 Feb 2025

Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 129,323,951 $1,183,258,435 +$141,190,764 $9.15 163
2025 Q2 114,653,135 $627,154,153 +$139,569,505 $5.47 153
2025 Q1 88,130,237 $554,340,184 +$59,175,189 $6.29 137
2024 Q4 79,496,969 $329,526,035 +$80,359,022 $4.12 109
2024 Q3 58,119,888 $194,118,470 +$7,244,002 $3.34 92
2024 Q2 55,906,669 $166,602,895 +$12,771,260 $2.98 76
2024 Q1 51,561,502 $177,886,781 -$90,828 $3.45 79
2023 Q4 52,233,706 $69,993,370 -$4,018,362 $1.34 62
2023 Q3 48,682,678 $106,127,667 -$321,362 $2.18 55
2023 Q2 48,822,080 $116,683,910 +$12,840,858 $2.39 53
2023 Q1 43,462,507 $80,405,139 +$498,873 $1.85 35
2022 Q4 43,185,947 $83,348,629 -$3,845,159 $1.93 36
2022 Q3 45,770,959 $70,490,000 +$26,192,291 $1.54 37
2022 Q2 28,751,331 $80,790,000 +$28,742,730 $2.81 31
2022 Q1 7,161,506 $15,754,000 +$2,083,345 $2.2 20
2021 Q4 13,166,532 $10,286,000 -$218,769 $0.7822 15
2021 Q3 12,448,249 $17,424,000 -$63,952 $1.4 15
2021 Q2 12,478,497 $28,076,000 -$1,746,455 $2.25 15
2021 Q1 13,128,768 $35,591,000 +$338,711 $2.71 17
2020 Q4 13,007,586 $31,748,000 -$644,938 $2.42 17
2020 Q3 13,263,517 $53,451,000 -$728,128 $4.03 13
2020 Q2 13,374,829 $88,003,000 -$1,315,702 $6.58 12
2020 Q1 13,964,620 $45,943,000 -$779,902 $3.29 17
2019 Q4 14,179,323 $53,174,000 -$140,814 $3.75 16
2019 Q3 14,115,568 $63,519,000 -$267,929 $4.5 17
2019 Q2 14,171,891 $106,290,000 +$106,290,000 $7.5 18